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Background. The goal of this study was to determine whether leukemia inhibitory factor (LIF) promotes anti-inﬂammatory activity
after stroke in a sex-dependent manner. Methods. Aged (18-month-old) Sprague-Dawley rats of both sexes underwent sham
surgery or permanent middle cerebral artery occlusion (MCAO). Animals received three doses of intravenous LIF (125 μg/kg)
or PBS at 6, 24, and 48 h before euthanization at 72 h. Spleen weights were measured immediately following euthanization.
Western blot was used to measure protein levels of CCL8, CD11b, CXCL9, CXCL10, IL-12 p40, IL-3, and the LIF receptor
(LIFR) in spleen tissue. ELISA was used to measure IL-1β, IL-6, TNFα, and IFNγ in spleen tissue. A Griess Assay was used to
indirectly quantify NO levels via measurement of nitrite. Levels of cellular markers and inﬂammatory mediators were
normalized to the baseline (sham) group from each sex. Statistical analysis was performed using two-way ANOVA and followed
by Fisher’s LSD post hoc test. Results. Aged female rats showed a signiﬁcantly lower spleen weight after MCAO, but showed a
signiﬁcant increase in spleen size after LIF treatment. This eﬀect was observed in aged male rats, but not to as great of an extent.
CD11b levels were signiﬁcantly higher in the spleens of MCAO+PBS males compared to their female counterparts, but there
was no signiﬁcant diﬀerence in CD11b levels between MCAO+LIF males and females. LIF signiﬁcantly increased CXCL9 after
LIF treatment in aged male and female rats. LIFR and IL-3 were upregulated after LIF treatment in aged females. Splenic nitrate
increased after MCAO but decreased after LIF treatment in aged females. Splenic nitrate levels did not increase after MCAO but
did increase after LIF treatment in aged males. The following cytokines/chemokines were not altered by sex or treatment: TNFα,
IL-6, IL-12 p40, CCL8, IFNγ, and CXCL10. Conclusions. LIF treatment after permanent MCAO induces sex-dependent eﬀects
on the poststroke splenic response and the production of proinﬂammatory cytokines among aged rats.

1. Introduction
Ischemic stroke is currently the ﬁfth leading cause of death in
the United States and one of the leading causes of adult disability. The most damaging type of stroke, an emergent large
vessel occlusion (ELVO) occurs when a thrombus blocks
ﬂow to one of the brain’s major arteries [1]. While intravenous tissue plasminogen activator (tPA) is eﬀective at treating small-vessel strokes, it is often ineﬀective at restoring
blood ﬂow during an ELVO [2–4]. ELVO patients may
undergo endovascular thrombectomy (EVT), in which a

stent retriever is used to retrieve the thrombus from the
occluded vessel, up to 24 h after the patient’s last known normal [5]. Patients who are ineligible for EVT are extremely
limited concerning their treatment options. Furthermore,
the prognosis for ELVO without recanalization is extremely
dismal; most patients are at risk of death or left with severe
deﬁcits in sensorimotor skills and cognition [6].
While acute energy failure is responsible for the initial
phase of neuronal death, the majority of tissue damage
occurs hours to days after the onset of stroke [7, 8]. Microglia
activated by substances released from dying neurons
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produce proinﬂammatory mediators that compromise the
blood-brain barrier [9–13]. During this period, increased
adrenergic signaling in splenic nerves promotes contraction of the spleen and release of splenocyte populations
into the peripheral circulation [14–18]. The breakdown
of the blood-brain barrier usually coincides with the production of matrix metalloproteinases by activated microglia [10, 19, 20]. Splenocytes inﬁltrate the ischemic tissue
and further perpetuate the inﬂammatory cascade through
the subsequent release of inﬂammatory mediators and
reactive oxygen species [21]. This poststroke splenic
response has been observed in human stroke patients in
addition to rodents [22].
Interferon-gamma (IFNγ), a proinﬂammatory cytokine
produced by CD4+ T cells, CD8+ T cells, and NK cells, is
largely responsible for initiating the peripheral immune
response after stroke [23, 24]. Upon stimulation with proinﬂammatory cytokines such as IL-2 and IL-12, T cells release
IFNγ, which stimulates the production of CXCL10 in
monocytes/macrophages and microglia [25–28]. Oﬀner
et al. showed that several proinﬂammatory chemokines,
including CXCL10, are upregulated 22 h after stroke [29].
CXCL10, which increases intracellular calcium through
binding to CXCR3, promotes chemotaxis of T cells and
other peripheral leukocytes towards the site of injury [30–
32]. Administration of antibodies to block the
IFNγ/CXCL10 signaling yields a signiﬁcant decrease in the
infarct volume and prevents the reduction in spleen size at
72 h after stroke [24]. Furthermore, blocking this signaling
pathway signiﬁcantly reduced the poststroke inﬁltration of
immune response into the brain [23, 24].
Leukemia inhibitory factor (LIF), a cytokine in the IL6 family, has shown eﬃcacy in promoting cellular survival
and countering peripheral inﬂammation when administered intravenously after permanent stroke [33–37]. LIF
activates several signaling pathways, including the
PI3K/Akt signaling cascade, which promotes the upregulation of antioxidant enzymes including metallothionein III
and peroxiredoxin IV in oligodendrocytes and superoxide
dismutase 3 in neurons [34, 35]. Also, LIF treatment promotes anti-inﬂammatory signaling by decreasing splenic
levels of IFNγ and preventing the upregulation of CXCL10
that occurs after stroke [36]. However, these studies were
performed in 3-month-old male rats, which are equivalent
age-wise to adolescent male humans. Considering that the
risk of stroke doubles with every decade after the age of
55, the use of young animals of one sex to mimic human
stroke patients is not an optimal model.
Recently, this group demonstrated that administration of
LIF at 6, 24, and 48 h after MCAO promotes partial motor
skill recovery in aged female rats, but does not signiﬁcantly
decrease tissue damage [38]. This phenomenon is attributed
to the signiﬁcantly lower levels of LIFR in the brain tissue
of aged males and females compared to young male rats.
However, very little is known about the role of the aged
immune system in poststroke pathophysiology. This manuscript explores how LIF treatment modulates the splenic
inﬂammatory response after stroke in an age-dependent
and sex-dependent manner.
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2. Materials and Methods
Retired breeding pairs of Sprague-Dawley rats (9-10 mo.)
were purchased from Envigo (Indianapolis, IN) and housed
until they reached the age of 18-19 mo. All animals were kept
in a climate-controlled room and allowed access to food and
water ad libitum. Animals were kept on a 12 h light/dark
cycle (07:00–19:00 h). All animals were randomly assigned
to treatment groups before surgical procedures, and sample
sizes were calculated using StatMate software (GraphPad,
San Diego, CA). All procedures were approved according to
the University of Kentucky Institutional Animal Care and
Use Committee.
2.1. Middle Cerebral Artery Occlusion. Permanent focal cerebral ischemia was induced using the intraluminal middle
cerebral artery occlusion (MCAO) model as previously
described [39]. A 40 mm monoﬁlament was introduced
through the ligated external carotid artery and advanced
through the internal carotid artery. The ﬁlament was
advanced until it reached the origin of the middle cerebral
artery. Animals subjected to the sham MCAO procedure
were anesthetized and underwent exposure of the common
carotid artery without subsequent occlusion of the middle
cerebral artery.
2.2. Drug Treatment. All animals were treated prophylactically with ketoprofen (10 mg/kg s.c.) and atropine
(0.25 mg/kg s.c.) with two additional doses of ketoprofen at
24 and 48 h post-MCAO. Recombinant human LIF (ProSpec,
Ness Ziona, Israel) (125 μg/kg) or PBS (pH 7.4) was administered intravenously at 6, 24, and 48 h post-MCAO as previously described [34, 35]. Animals were randomly assigned
to treatment groups, and all lab personnel administering
drugs were blinded to treatments.
2.3. Tissue Collection. Rats were euthanized at 72 h postMCAO via intraperitoneal injection of ketamine/xylazine
solution (75 mg/kg and 7.5 mg/kg) [23]. Spleens were collected immediately before perfusion. Animals used for biochemical analysis were perfused with saline before
obtaining tissue.
2.4. Tissue Homogenization. To obtain whole-cell extracts,
frozen tissue was homogenized in a whole-cell lysis buﬀer
containing the following: 50 mM Tris pH 8, 150 mM NaCl,
0.1% SDS, 1% IGEPAL, 1 mM PMSF, and a complete Mini
protease inhibitor cocktail (Roche Diagnostics, Indianapolis,
IN). An electric homogenizer was used to disrupt tissue, and
lysates were incubated on ice for 20 min. Tissue lysates were
vortexed and pipetted to break up nuclei. Protein concentrations were determined by performing a Bradford Assay
according to the manufacturer’s protocol (Bio-Rad, Hercules,
CA). Brieﬂy, a Bradford reagent containing Coomassie blue
was added to the diluted protein samples, and absorbance
was read at 595 nm using a SmartSpec 3000 spectrophotometer (Bio-Rad). Concentrations were determined by comparing the absorbance readings against a standard curve.
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2.6. Griess Assay. For indirect measurement of NO production, a Griess Assay Kit (Molecular Probes, Eugene, OR),
was used to measure nitrite (NO2-) levels in the spleen tissue
from aged rats. The assay was performed according to the
manufacturer’s protocol. The concentration of NO2- in each
spleen sample was normalized to the protein concentration
and expressed in terms of % baseline (sham) levels.
2.7. ELISA. To measure the release of IFNγ, TNFα, IL-1β, IL6, and IL-10 in spleen tissue, ELISA was performed as previously described according to the manufacturer’s protocol
using the appropriate DuoSet ELISA kits (R&D Systems,
Inc., Minneapolis, MN). The concentration of the cytokine
in each spleen sample was normalized to the protein concentration and expressed in terms of % baseline (sham) levels.
2.8. Data Analysis. All data are expressed as the mean ± the
standard error of the mean. All data from treatment groups
were normalized to the mean of the respective sham group
from each sex. Statistical analysis was performed using
GraphPad Prism 8.4.3. Software (La Jolla, CA). Data were
analyzed using a two-way ANOVA followed by Fisher’s protected LSD post hoc test to determine statistical signiﬁcance.
If a signiﬁcant interaction was found within the two-way
ANOVA, individual diﬀerences were determined using Fisher’s protected LSD post hoc test. A p-value of less than 0.05
was considered statistically signiﬁcant. All reported p-values
are two-tailed.

3. Results
3.1. LIF Treatment Increases Spleen Weight after MCAO in
Aged Animals. Spleen weights were measured immediately
following euthanization at 72 h after MCAO and normalized
to the mean spleen weight from aged male and aged female
rats. There was a signiﬁcant eﬀect of drug treatment on

200
Spleen weight (% of sham)

2.5. Western Blot. Western blot analysis was used for semiquantitative measurement of protein expression using a previously described procedure [35]. Brieﬂy, whole-cell lysates
from spleen tissue were run on SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were
blocked with 5% nonfat milk in TBS and probed with the following antibodies: rabbit anti-LIFR (C-19) (1 : 100; Santa
Cruz Biotechnology, Dallas, TX, US), rabbit anti-IL-12 p40
(1 : 100; ABBiotech, San Diego, CA), rabbit anti-CXCL10
(1 : 5000; Abcam, San Francisco, US), rabbit anti-IL-3 (R&D
Biosystems; Minneapolis, MN), rabbit anti-CXCL9
(1 : 1000; Fitzgerald Industries Int., North Action, MA),
rabbit-anti-CCL8 (1 : 500; Biorbyt, Cambridge, UK), and
mouse anti-CD11b (1 : 1000; Abcam). Membranes were
incubated in IRDye 800CW goat anti-rabbit antibodies
(1 : 20,000; Li-Cor) for the detection of protein bands. Membranes were visualized using the Odyssey CLx Imaging System (Li-Cor). To normalize for loading, membranes
containing whole-cell extracts were reprobed with mouse
anti-β-actin (1 : 5000; Novus Biologicals) and IRDye 680RD
goat anti-mouse antibodies (1 : 20,000; Li-Cor). Western blot
bands were quantiﬁed using ImageJ software (NIH,
Bethesda, MD).
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Figure 1: LIF treatment increases spleen weight after MCAO in aged
animals. Spleen weights were measured after euthanization and
normalized to the average spleen weight for sham-operated male
(n = 9) and female animals (n = 8). The average spleen size among
LIF-treated males (n = 23) was signiﬁcantly higher than that among
PBS-treated males (n = 19; ∗∗ p < 0:01), but not sham males.
Although there was a signiﬁcant decrease in spleen size after
MCAO among female rats (∗∗∗ p < 0:001), spleens from LIF-treated
female rats were signiﬁcantly larger than spleens from sham
(∗∗∗ p < 0:001) and MCAO+PBS females (∗∗∗∗ p < 0:0001).
Furthermore, female MCAO+PBS rats (n = 14) showed a
signiﬁcantly larger decrease in spleen weight compared to PBStreated males (∗ p < 0:05). However, LIF-treated females (n = 16)
had signiﬁcantly larger spleens compared to their male counterparts
(∗∗∗ p < 0:001). Male sham n = 8‐24 per treatment group.

spleen weight (F 2,83 = 38:07; p < 0:0001) as well as a signiﬁcant interaction between sex and treatment (F 2,83 = 10:71; p
< 0:0001). While there was a signiﬁcant decrease in spleen
size among female MCAO+PBS rats compared to sham
females (p < 0:001), the MCAO+LIF females had signiﬁcantly larger spleens than the MCAO+PBS females
(p < 0:0001) and sham females (p < 0:001). MCAO+PBS
males did not show signiﬁcant changes in spleen size compared to their sham counterparts, but MCAO+LIF males
had signiﬁcantly larger spleens compared to their MCAO
+PBS counterparts (p < 0:01). Furthermore, while MCAO
+PBS females showed a signiﬁcantly larger decrease in spleen
weight compared to their male counterparts (p < 0:05), the
MCAO+LIF females showed a signiﬁcantly larger increase
in spleen size after treatment compared to their male counterparts (p < 0:001; Figure 1).
3.2. Sex and Treatment Aﬀect Splenic LIFR and CD11b
Expression. Western blot was used to measure levels of LIFR
in the spleens of aged rats at 72 h after MCAO. Levels of LIFR
protein expression were normalized to respective sham levels
from each sex. There were signiﬁcant eﬀects of sex
(F 1,24 = 7:931; p = 0:0096) and treatment (F 1,24 = 19:79; p =
0:0002) on LIFR protein expression, as well as a signiﬁcant
interaction between the two factors (F 1,24 = 7:455; p =
0:0117). Spleens from LIF-treated females showed signiﬁcantly higher levels of relative LIFR expression compared to
PBS-treated animals of both sexes (p < 0:0001) and MCAO
+LIF males (p < 0:001). However, there was no signiﬁcant
diﬀerence between the spleen weights from LIF-treated males
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Figure 2: Sex and treatment aﬀect splenic LIFR and CD11b expression. (a) LIFR levels in the spleens from LIF-treated females (n = 5) were
signiﬁcantly higher than those in the spleens from PBS-treated females (n = 8; ∗∗ p < 0:01). However, there was no signiﬁcant diﬀerence
between the spleen weights from LIF-treated male rats (n = 8) and the spleen weights from PBS-treated males (n = 7). n = 3 for both sham
groups. (b) CD11b levels were signiﬁcantly higher in the spleens of PBS-treated male rats (n = 4) compared to PBS-treated females (n = 4;
∗∗
p < 0:01) and LIF-treated females (n = 4). However, there was was no signiﬁcant diﬀerence between LIF-treated males (n = 4) and LIFtreated females. n = 2 for both sham groups.

and PBS-treated males (Figure 2(a)). To determine levels of
CD11b in the spleen after stroke, spleen samples from animals euthanized 72 h after MCAO were analyzed via western
blot. Levels of relative CD11b expression in treatment groups
were normalized to those in sham groups of the same sex.
There was a signiﬁcant eﬀect of sex on CD11b expression
(F 1,12 = 11:73; p = 0:0050) and a signiﬁcant interaction
between sex and treatment (F 1,12 = 5:055; p = 0:0441). Relative CD11b expression was signiﬁcantly lower in the
MCAO+PBS female rats compared to MCAO+PBS males
(p < 0:01) and MCAO+LIF males (p < 0:05). Furthermore,
CD11b levels were signiﬁcantly higher in MCAO+PBS males
compared to MCAO+LIF females (p < 0:05). However, there
was no signiﬁcant diﬀerence in CD11b levels between LIFtreated males and females (Figure 2(b)).
3.3. Sex Aﬀects Splenic IL-1β, but Not TNFα or IL-6. ELISA
was used to measure levels of IL-1β in spleen tissue from
aged males and females at 72 h after stroke. There was a signiﬁcant eﬀect of treatment on IL-1β (F 1,24 = 5:251; p =
0:0310), but not due to sex. IL-1β levels were signiﬁcantly
higher in the spleens of MCAO+PBS females compared to
MCAO+LIF female rats (p < 0:05; Figure 3(a)). TNFα levels
in spleen tissue were also measured in the spleens of aged
male and female rats using ELISA. However, there were no
signiﬁcant eﬀects due to sex or drug treatment on splenic
TNFα levels (Figure 3(b)). IL-6 levels in splenic tissue were

also measured using ELISA; however, there were no signiﬁcant sex- or treatment-dependent alterations in IL-6 levels
(Figure 3(c)).
3.4. IL-12 p40 and CCL8 Levels Are Unchanged after MCAO
+LIF Treatment. Western blot was used to measure levels
of IL-12 p40 and CCL8 in the spleens of aged male and
female rats after MCAO and LIF treatment. There were no
signiﬁcant changes in IL-12 p40 levels due to sex or drug
treatment (Figure 4(a)). Furthermore, there were no signiﬁcant eﬀects of sex or treatment on relative CCL8 levels in
spleen tissue (Figure 4(b)).
3.5. MCAO+LIF Changes Levels of IFNγ-Inducible
Inﬂammatory Mediators but Not IFNγ. IFNγ levels were
measured in the spleens of aged rats using an ELISA kit.
There were no signiﬁcant changes in normalized IFNγ levels
due to sex or treatment (Figure 5(a)). Nitric oxide production
was indirectly measured by detecting levels of NO2- in spleen
tissue using a Griess Assay. The concentration of nitrite was
normalized to mM NO2- per mg of protein, and all treatment
groups were further normalized to those of their respective
sham groups. Although the main eﬀects of sex and treatment
on NO2- were not signiﬁcant, there was a signiﬁcant interaction between these two factors (F 1,27 = 10:08; p = 0:0037).
The MCAO+PBS female had signiﬁcantly higher levels of
NO2- compared to male MCAO+PBS rats (p < 0:01).
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Figure 3: IL-1β, but not TNFα or IL-6, is aﬀected by sex and treatment. (a) Among LIF-treated rats, aged females (n = 5) had signiﬁcantly
lower levels of IL-1β compared to their PBS-treated counterparts (n = 5; ∗ p < 0:05). However, there was no diﬀerence between the relative
IL-1β expression between PBS-treated males (n = 7) and LIF-treated males (n = 11). n = 4 for both sham groups. However, (b) TNFα
levels were not signiﬁcantly altered among PBS-treated males (n = 7), LIF-treated males (n = 10), PBS-treated females (n = 5), and LIFtreated females (n = 3). n = 3 for male sham and n = 4 for female sham groups. (c) Furthermore, IL-6 levels were not signiﬁcantly altered
among PBS-treated males (n = 8), LIF-treated males (n = 11), PBS-treated females (n = 6), and LIF-treated females (n = 3). n = 3 for both
sham groups.

However, LIF treatment signiﬁcantly reduced NO2- in female
rats compared to their MCAO+PBS counterparts (p < 0:05;
Figure 5(b)). IL-3 was measured in spleen tissue using western blot. There were signiﬁcant eﬀects due to sex
(F 1,22 = 17:87; p = 0:0003) and treatment (F 1,22 = 8:946; p =
0:0067). There was no diﬀerence between male and female
MCAO+PBS rats in terms of splenic IL-3. However, levels
of IL-3 in the spleens of MCAO+LIF females were signiﬁcantly higher than those of MCAO+PBS females (p < 0:01)
and MCAO+LIF male rats (p < 0:001; Figure 5(c)).
3.6. LIF Aﬀects Splenic CXCL9, but Not CXCL10 Levels. The
IFNγ-inducible chemokines CXCL9 and CXCL10 were measured in spleen tissue using western blot. The levels of
CXCL9 in the spleen were signiﬁcantly aﬀected by treatment
(F 1,11 = 19:17; p = 0:0011) but not by sex. Speciﬁcally, there
was a signiﬁcant increase in CXCL9 in the spleens of
MCAO+LIF male rats compared to MCAO+PBS male rats
(p < 0:01), and the MCAO+LIF female rats had signiﬁcantly
higher levels of CXCL9 compared to MCAO+PBS female rats
(p < 0:05; Figure 6(a)).

Previously, this lab demonstrated that LIF prevents the
stroke-mediated increase in splenic CXCL10 at 72 h after
stroke. However, among aged males and female rats, there
were no sex- or treatment-dependent changes in CXCL10
after MCAO and LIF treatment (Figure 6(b)).

4. Discussion
Several published studies have demonstrated that blocking
the spleen-mediated immune response can signiﬁcantly
reduce the inﬁltration of immune cells and subsequent brain
damage after stroke [16, 17, 40]. For example, Seifert et al.
showed that administration of antibodies against IFNγ after
stroke signiﬁcantly reduces tissue damage at 72 h after stroke
[23, 24]. Other studies involving the administration of therapies such as human umbilical cord blood cells [21, 41] and
the sigma receptor agonist 1,3-Di-o-tolylguanidine show that
blocking the splenic response is associated with positive outcomes and reduced brain damage after MCAO.
Although the spleen weights are signiﬁcantly increased
after LIF treatment in both male and female aged rats, the
results of this study indicate that female rats show a more
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Figure 4: Sex and treatment do not alter IL-12 p40 or CCL8. (a) There were no signiﬁcant eﬀects of sex or drug treatment on IL-12 p40 levels
in the spleens of MCAO+PBS male (n = 4) and female rats (n = 4). Furthermore, there were no signiﬁcant changes in relative p40 levels after
MCAO+LIF treatment in male (n = 4) and female (n = 4) rats. n = 2 for both sham groups. (b) There were no signiﬁcant eﬀects of sex or drug
treatment on CCL8 levels in the spleens of MCAO+PBS male (n = 5) and female rats (n = 5). Furthermore, there were no signiﬁcant changes
in relative p40 levels after MCAO+LIF treatment in male (n = 5) and female (n = 5) rats per treatment group. n = 4 for both sham groups.

robust increase in spleen weight compared to their male
counterparts. A previous study by this laboratory showed
that administration of LIF at 24, 48, and 72 h after stroke
did not signiﬁcantly decrease edema or cytotoxicity, although
there was a trend towards decreased brain damage among
female LIF-treated rats. However, aged female rats demonstrated partial motor skill recovery according to two out of
the four assessments, while their male counterparts did not
show recovery according to any of the four tests. Since levels
of LIFR in the brains of aged female rats were lower than
those of aged male rats after stroke, the partial recovery
observed in aged female rats after LIF treatment may be
attributed to stronger anti-inﬂammatory activity [38].
Among young male rats, CD11b expression signiﬁcantly
decreased after MCAO and was not aﬀected by LIF treatment
[36]. Most likely, this pattern of expression is due to the
migration of CD11b+ cells from the spleen to the peripheral
circulation after stroke. This hypothesis is consistent with
what we observed between male and female MCAO+PBS
animals; the female animals had signiﬁcantly lower levels of
relative splenic CD11b expression as well as signiﬁcantly
smaller spleens compared to their male counterparts.
CD11b levels were signiﬁcantly higher in the spleens of
MCAO+LIF females compared to their PBS-treated counterparts, which reﬂects the increased spleen weight observed
after LIF treatment. However, the increase in spleen size after
LIF treatment is much more pronounced than the increase in
CD11b levels, which suggests that cell surface expression of
CD11b may decrease after LIF treatment. Since CD11b surface expression is an indicator of an inﬂammatory phenotype
[42], its downregulation would suggest anti-inﬂammatory

activity. Further studies using ﬂow cytometry will be necessary to conﬁrm the speciﬁc eﬀects of LIF on the cell surface
expression of CD11b in immune cells.
The larger increase in spleen size observed after LIF treatment in female rats may also be explained by greater expression of LIFR on splenocytes seen in female rats after LIF
treatment. The upregulation of splenic LIFR could be due
to a higher number of LIFR+ cells returning to the spleen
after LIF treatment. While LIF causes an increase in spleen
size in both male and female rats, only females show an
upregulation of splenic LIFR after MCAO+LIF treatment.
These results also demonstrate that male rats show a diﬀerential response in LIFR expression between young males and
aged males; according to a previous study from our lab,
young males show decreased LIFR after LIF treatment while
aged males show no signiﬁcant change in splenic LIFR levels.
However, the increase in spleen size after LIF treatment in
aged male rats might obscure any changes in the number of
LIFR+ splenocytes, since young male rats do not show a signiﬁcant change in spleen size after LIF treatment [36].
Previously, this laboratory demonstrated that LIF treatment signiﬁcantly reduced splenic IFN-gamma and prevented the upregulation of CXCL10 after stroke [36]. Seifert
et al. demonstrated that the IFNγ/CXCL10 axis is crucial
for promoting the chemotaxis of immune cells, speciﬁcally
CD3+CD4+ Th1/Th17 and CD3+CD8+ cytotoxic T cells,
to the infarct [18, 23, 24]. Although IFNγ levels were not
changed after MCAO or LIF treatment, LIF signiﬁcantly
decreased the concentration of NO2-, which is a byproduct
of NO breakdown, in the spleens of aged female rats but
not aged male rats. Decreased NO2- levels are likely due to
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Figure 5: Sex and treatment change levels of IFNγ and IFNγ-inducible inﬂammatory mediators. (a) There was no signiﬁcant diﬀerence in
IFNγ levels in the spleens of male or female rats after MCAO. n = 4 per treatment group for all groups except sham groups (n = 2). (b)
Relative levels of NO2- were signiﬁcantly higher among MCAO+PBS females (n = 7) compared to MCAO+PBS males (n = 10). LIF
signiﬁcantly decreased NO2- in the spleens of female rats (n = 8) compared to the MCAO+PBS female rats (n = 7; ∗ p < 0:05). There was
no signiﬁcant diﬀerence in relative NO2- levels between MCAO+LIF male rats (n = 6) and MCAO+PBS male rats. n = 5 for male sham
and n = 4 for female sham groups. (c) MCAO+LIF-treated female rats (n = 5) had signiﬁcantly higher levels of IL-3 in the spleen
compared to MCAO+PBS females (n = 6; ∗∗ p < 0:01) and MCAO+LIF males (n = 8; ∗∗∗ p < 0:001). However, there were no diﬀerences
between MCAO+PBS males (n = 7) and MCAO+LIF males. n = 2 for male sham group and n = 5 for female sham group.

the changes in inducible nitric oxide synthase (iNOS) activity
and subsequent NO production [43, 44]. IFNγ released from
T cells [25] and NK cells [45] increases iNOS expression in
monocytes and neutrophils [46], which promotes NO production and the accumulation of NO2-. Although relative
IFNγ levels were not signiﬁcantly decreased after LIF treatment in female rats, iNOS expression may be mediated
together by IL-1β and IFNγ [47]. Therefore, the lower
NO2- levels observed in spleens of female rats are attributed
to the sex-dependent eﬀect of LIF on IL-1β production.
Sex-speciﬁc diﬀerences in the production of other proinﬂammatory cytokines such as IL-1β might be responsible for the
diﬀerential eﬀect of LIF on IFNγ levels in the spleen. Posma
et al. previously showed that males have higher numbers of
IL-1β-producing monocytes in the blood compared to
females due to higher blood levels of testosterone [48].
Although LIF treatment prevented the increase in splenic
CXCL10 in young male rats, we did not observe a signiﬁcant

change in splenic CXCL10 levels after a stroke or LIF treatment among aged rats of either sex [36]. The return of
CXCL10+ splenocytes to the spleen after LIF treatment
may have obscured any changes in its intracellular expression. However, we did observe a signiﬁcant upregulation in
the cytokine IL-3 and the IFNγ-inducible chemokine CXCL9
after MCAO+LIF treatment in aged animals of both sexes.
Although the higher levels of these cytokines might be
explained by a higher number of CXCL9-producing monocytes and IL-3-producing T cells in the spleen, upregulation
of chemotactic cytokines may provide a beneﬁcial role after
stroke by drawing inﬂammatory cells away from the brain
[49]. For instance, HUCB cells cause splenocytes to return
to the spleen after stroke via the secretion of potent chemotactic cytokines [49, 50].
CXCL9, alternatively known as monokine induced by
IFNγ, is a potent inducer of T cell chemotaxis that signals
through CXCR3 [51]. Therefore, the increase in spleen size
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Figure 6: LIF aﬀects splenic CXCL9, but not CXCL10, levels. (a) There was a signiﬁcant increase in splenic CXCL9 among MCAO+LIF rats
(n = 4) compared to MCAO+PBS rats (n = 4; ∗∗ p < 0:01). Furthermore, LIF treatment increased CXCL9 expression in female rat (n = 3)
compared to MCAO+PBS female (n = 4; ∗ p < 0:05) levels. n = 2 for both sham groups. (b) There was no signiﬁcant change in splenic
CXCL10 levels due to treatment or sex after MCAO. n = 4 for all treatment groups except both sham groups (n = 2).

observed after LIF treatment in both sexes might be the result
of CXCL9-mediated chemotaxis of T cells from the peripheral circulation back to the spleen. Little is known about the
role of IL-3 in ischemic stroke; however, it is produced by
activated CD4+/CD8+ T cells and has been implicated in
the development of neuroinﬂammatory conditions such as
multiple sclerosis [52, 53]. Although IL-3 is mainly a chemotactic factor for eosinophils [54], it has also been shown to
regulate the expression of CXCL9 [55] and act synergistically
with the chemokine CXCL12 to promote T cell chemotaxis.
Notably, Renner et al. demonstrated that treatment with
anti-IL-3 antibodies decreased leukocytic inﬁltration among
patients with relapsing-remitting multiple sclerosis. Since
IL-3 is secreted by T cells [56], the higher level of IL-3 and
CXCL9 observed after LIF treatment could also be explained
by a higher number of T cells in the spleen.
The results of this study demonstrate the necessity of
using age-appropriate animal models that take sex as a biological variable into account. Preclinical and clinical studies
testing the eﬃcacy of potential anti-inﬂammatory and neuroprotective treatments for stroke demonstrate that certain
drugs are eﬃcacious in male, but not female, patients and
vice versa. For instance, minocycline, an antibiotic and
poly-ADP ribose polymerase inhibitor, only demonstrated
neuroprotective eﬃcacy in male mice after ischemic stroke,
but not ovariectomized female mice [57]. A subsequent clinical study mirrored the sex-dependent eﬀects of the initial
preclinical study; while male patients showed recovery after
minocycline administration, there was no observable eﬀect
in female patients [58]. A clinical study using uric acid as a
neuroprotective agent against ischemic stroke is further evidence of the need to take sex as a biological variable into
account when examining poststroke outcomes. While initial
results suggested that uric acid did not improve outcomes,

further analysis of the data showed that female patients experienced positive outcomes after treatment [59]. Our previous
study, which showed that aged female rats, but not aged male
rats, showed motor skill recovery after LIF treatment, further
demonstrates the need to examine neuroprotective therapeutics in age-appropriate models of both sexes [38].
Although this study provided insight regarding the eﬀect
of LIF on the poststroke immune response in aged male and
female animals, some limitations need to be discussed. While
western blot analysis and ELISA demonstrate relative
changes in levels of inﬂammatory mediators compared to
baseline (sham) and PBS treatment, it does not provide
inﬂammation on cell-speciﬁc level markers such as
CD11b/LIFR. Furthermore, western blots do not provide
information about which cell types are responsible for
expressing these mediators. Therefore, future studies using
ﬂow cytometry and immunohistochemistry will be necessary
to conﬁrm the anti-inﬂammatory mechanisms of LIF in aged
animals and determine which splenocyte populations are the
most responsive to LIF treatment.

5. Conclusion
Through these experiments, we have shown that LIF exerts
stronger anti-inﬂammatory eﬀects on the poststroke splenic
response in aged female rats, but not male rats. We believe
these eﬀects were due to the upregulation of chemotactic
cytokines as well as the downregulation of inﬂammatory
mediators such as NO and IL-1β in the splenocytes of aged
female rats. Future studies using ﬂow cytometry will be used
to determine whether higher levels of cytokines such as
CXCL9 and IL-3 are due to higher numbers of T cells and
monocytes/macrophages with the spleen or higher production by each cell.
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